SINGULAIR (montelukast sodium) by Merck & Co. is leukotriene receptor antagonists [moa]. First approved in 1998.
Drug data last refreshed 2d ago
SINGULAIR (montelukast sodium) is an oral leukotriene receptor antagonist approved in 1998 for asthma and allergic rhinitis. It works by blocking leukotrienes, inflammatory mediators that trigger airway constriction and allergic responses. Available as tablets and chewable formulations, it provides once-daily oral dosing as an alternative to inhaled controllers.
Product faces imminent patent expiration with limited growth opportunity; commercial teams typically focus on market defense and generic transition planning.
Leukotriene Receptor Antagonists
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers
Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers
Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects
A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)
Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)
Worked on SINGULAIR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SINGULAIR offers limited upside for ambitious pharma professionals; the product is in advanced age with shrinking market opportunity due to generic competition and superior biologics. Career value lies primarily in defensive commercial execution, market access strategy, and pipeline transition roles at Merck.